Similarly, in unresectable stage III NSCLC, a phase II clinical trial has evaluated the induction treatment with SHR-1701 (a bifunctional agent composed of an IgG4 monoclonal antibody targeting PD-L1 fused with extracellular domain of the TGF-beta II receptor) with or without chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.